Verastem, Inc. (VSTM) Operating Margin
- Operating margin · 12 months: Value -182.57%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -182.57% | Operating income / revenue. Period ending 2026-06-30. $-159.80M ÷ $87.53M × 100 ≈ -182.57% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -159.80M USD | Operating Income (Loss) |
| Revenue | 87.53M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 140.22M USD | Research and Development Expense |
| Selling, general and administration | 95.16M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-159.80M | $87.53M | (m) | $140.22M | $95.16M | -182.57% |
| 2026-03-31 | $-170.85M | $49.59M | (m) | $123.67M | $88.42M | -344.56% |
| 2025-12-31 | $-170.13M | $30.91M | (m) | $114.60M | $81.15M | -550.33% |
| 2025-09-30 | $-160.24M | $13.38M | (m) | $103.74M | $67.48M | -1197.73% |
| 2025-06-30 | $-156.56M | $2.14M | (m) | $99.50M | $58.75M | -7326.11% |
| 2025-03-31 | $-131.07M | (m) | (m) | $92.78M | $48.29M | (m) |
| 2024-12-31 | $-114.96M | $10.00M | (m) | $81.33M | $43.62M | -1149.56% |
| 2024-09-30 | $-114.50M | (m) | (m) | $83.03M | $41.48M | (m) |
| 2024-06-30 | $-98.78M | (m) | (m) | $72.22M | $36.57M | (m) |
| 2024-03-31 | $-100.80M | (m) | (m) | $67.05M | $33.75M | (m) |
| 2023-12-31 | $-92.08M | (m) | (m) | $61.36M | $30.73M | (m) |
| 2023-09-30 | $-77.79M | (m) | (m) | $49.59M | $28.20M | (m) |
| 2023-06-30 | $-74.19M | (m) | (m) | $46.94M | $27.25M | (m) |
| 2023-03-31 | $-75.30M | (m) | (m) | $48.93M | $26.37M | (m) |
| 2022-12-31 | $-72.94M | $2.60M | (m) | $50.56M | $24.98M | -2809.59% |
| 2022-09-30 | $-72.60M | $3.14M | (m) | $51.21M | $24.53M | -2311.43% |
| 2022-06-30 | $-69.74M | $3.14M | (m) | $49.25M | $23.63M | -2218.87% |
| 2022-03-31 | $-64.28M | $3.64M | (m) | $44.09M | $23.83M | -1764.51% |
| 2021-12-31 | $-61.41M | $2.05M | (m) | $39.35M | $24.11M | -2991.18% |
| 2021-09-30 | $-61.65M | $2.01M | (m) | $38.10M | $25.55M | -3061.17% |
| 2021-06-30 | $-31.79M | $80.66M | (m) | $39.73M | $40.64M | -39.41% |
| 2021-03-31 | $-37.11M | $84.47M | (m) | $39.35M | $49.37M | -43.93% |
| 2020-12-31 | $-49.36M | $88.52M | (m) | $41.38M | $62.76M | -55.76% |
| 2020-09-30 | $-65.90M | $91.63M | (m) | $43.68M | $79.39M | -71.92% |
| 2020-06-30 | $-107.02M | $22.01M | (m) | $44.94M | $80.93M | -486.18% |
| 2020-03-31 | $-124.03M | $20.84M | (m) | $46.94M | $94.78M | -595.12% |
| 2019-12-31 | $-132.34M | $17.46M | (m) | $45.78M | $101.21M | -758.14% |
| 2019-09-30 | $-133.31M | $15.05M | (m) | $42.08M | $103.68M | -885.77% |
| 2019-06-30 | $-128.77M | $21.52M | (m) | $41.44M | $106.96M | -598.25% |
| 2019-03-31 | $-108.69M | $28.39M | (m) | $42.47M | $93.47M | -382.87% |
| 2018-12-31 | $-94.78M | $26.72M | $165.00K | $43.65M | $77.27M | -354.75% |
| 2018-09-30 | $-78.58M | (m) | (m) | $46.14M | (m) | (m) |
| 2018-06-30 | $-80.14M | (m) | (m) | $52.31M | (m) | (m) |
| 2018-03-31 | $-75.42M | (m) | (m) | $48.97M | (m) | (m) |
| 2017-12-31 | $-67.80M | (m) | (m) | $46.42M | (m) | (m) |
| 2017-09-30 | $-61.55M | (m) | (m) | $42.06M | (m) | (m) |
| 2017-06-30 | $-46.47M | (m) | (m) | $28.54M | (m) | (m) |
| 2017-03-31 | $-41.72M | (m) | (m) | $23.98M | (m) | (m) |
| 2016-12-31 | $-37.00M | (m) | (m) | $19.78M | (m) | (m) |
| 2016-09-30 | $-37.16M | (m) | (m) | $20.57M | (m) | (m) |
| 2016-06-30 | $-44.64M | (m) | (m) | $27.66M | (m) | (m) |
| 2016-03-31 | $-51.39M | (m) | (m) | $34.22M | (m) | (m) |
| 2015-12-31 | $-58.20M | (m) | (m) | $40.56M | (m) | (m) |
| 2015-09-30 | $-60.24M | (m) | (m) | $42.56M | (m) | (m) |
| 2015-06-30 | $-58.09M | (m) | (m) | $40.30M | (m) | (m) |
| 2015-03-31 | $-55.72M | (m) | (m) | $37.56M | (m) | (m) |
| 2014-12-31 | $-53.61M | (m) | (m) | $35.45M | (m) | (m) |
| 2014-09-30 | $-51.00M | (m) | (m) | $33.56M | (m) | (m) |
| 2014-06-30 | $-48.26M | (m) | (m) | $31.30M | (m) | (m) |
| 2014-03-31 | $-45.45M | (m) | (m) | $29.05M | (m) | (m) |
| 2013-12-31 | $-41.40M | (m) | (m) | $25.93M | (m) | (m) |
| 2013-09-30 | $-37.98M | (m) | (m) | $22.22M | (m) | (m) |
| 2013-06-30 | $-37.77M | (m) | (m) | $23.57M | (m) | (m) |
| 2013-03-31 | $-34.38M | (m) | (m) | $22.20M | (m) | (m) |
| 2012-12-31 | $-32.23M | (m) | (m) | $21.71M | (m) | (m) |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $-13.70M | (m) | (m) | $9.88M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |